Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists

Journal of Bone Oncology

Volumn 2, Issue 1, 2013, Pages 38-46

  Kuchuk, Iryna ^a   Mazzarello, Sasha ^a   Butterfield, Kevin ^b   Appleton, Anthony ^c   Addison, Christina L ^d   Clemons, Mark ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Modern Dentistry   (Australia)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Bisphosphonate; Bone metastasis; Bone targeted agent; ONJ

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE GLUCONATE; DENOSUMAB; HYDROGEN PEROXIDE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BACTERIAL INFECTION; BONE REMODELING; BREAST CANCER; CANCER PATIENT; DISEASE COURSE; DRUG SAFETY; HUMAN; JAW OSTEONECROSIS; MEDLINE; METASTASIS; MOUTH HYGIENE; MOUTH INFECTION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; TREATMENT DURATION;

EID: 84882327058     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.12.001     Document Type: Review

References (78)

1. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment (Winchester, England) 2004;8: 1-176.
2. Hadji P. Managing bone health with zoledronic acid: a review of randomized clinical study results. Climacteric: The Journal of the International Menopause Society 2011;14: 321-32.
3. Hegarty A, Georgakopolou E, Porter S. Bisphosphonate-related osteochem-onecrosis of the jaws. British Journal of Hospital Medicine (London, England: 2005) 2008;69: 158-62.
4. Magremanne M, Vervaet C, Dufrasne L, Declercq I, Legrand W, Daelemans P. Bisphosphonates and maxillo-mandibular osteo(chemo)necrosis. Revue de Stomatologie et de Chirurgie Maxillo-faciale 2006;107: 423-8.
5. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. Australian Endodontic Journal: The Journal of the Australian Society of Endodontology Inc. 2009;35: 119-30.
6. Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatologica 2010;59(181- 203): 4-13.
7. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteone-crosis of the jaw in patients with cancer. Journal of Oncology Practice/American Society of Clinical Oncology 2006;2: 7-14.
8. Outcomes of bisphosphonate-related osteonecrosis of the jaw - importance of staging and management guidelines: a large single institutional update. Abstract no. 20526; 2008.
9. Jacobsen C, Metzler P, Obwegeser J, Zemann W, Gra TzK. Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years? Swiss Medical Weekly 2012;142: 0.
10. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteone-crosis of the jaw. Hematology/The Education Program of the American Society of Hematology American Society of Hematology Education Program 2006;356-60: 515.
11. Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS. Bisphosphonate-induced osteonecrosis of the jaw. The Annals of Pharmacotherapy 2007;41: 276-84. (Pubitemid 46340058)
12. Chaturvedi P, Pai PS, Chaukar DA, Gupta S, D'Cruz AK. Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2010;36: 541-5.
13. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 2007;22: 1479-91. (Pubitemid 351229318)
14. Bonafe-Oliveira L, Faltin RM, Arana-Chavez VE. Ultrastructural and histo-chemical examination of alveolar bone at the pressure areas of rat molars submitted to continuous orthodontic force. European Journal of Oral Sciences 2003;111: 410-6. (Pubitemid 37467763)
15. Shimizu M, Sasaki T, Ishihara A, Furuya R, Kawawa T. Bone wound healing after maxillary molar extraction in ovariectomized aged rats. Journal of Electron Microscopy 1998;47: 517-26. (Pubitemid 28560661)
16. Linkhart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 1996;19: 1S-12S. (Pubitemid 26254474)
17. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nature Clinical Practice Oncology 2007;4: 711-21. (Pubitemid 350187006)
18. Fleisch H. Bisphosphonates: mechanisms of action. Endocrine Reviews 1998;19: 80-100. (Pubitemid 29122075)
19. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. The Lancet Oncology 2006;7: 508-14. (Pubitemid 43779167)
20. Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, et al. Serum VEGF levels as predictive marker of bisphosphonate-related osteone-crosis of the jaw. Journal of Hematology & Oncology 2012;5: 56.
21. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. The Journal of Pharmacology and Experimental Therapeutics 2002;302: 1055-61. (Pubitemid 34920226)
22. Mawardi H, Giro G, Kajiya M, Ohta K, Almazrooa S, Alshwaimi E, et al. A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. Journal of Dental Research 2011;90: 1339-45.
23. Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, et al. Actinomycosis of the jaws - histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Archiv: An International Journal of Pathology 2007;451: 1009-17. (Pubitemid 350165265)
24. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. Journal of the American Dental Association (1939) 2009;140: 1259-65.
25. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. Journal of Dental Research 2011;90: 439-44.
26. Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ, et al. ONJ in two dental practice-based research network regions. Journal of Dental Research 2011;90: 433-8.
27. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. Journal of Cancer Research and Clinical Oncology 2010;136: 1117-24.
28. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 2008;23: 826-36. (Pubitemid 351768801)
29. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bispho-sphonates: incidence and risk factors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005;23: 8580-7. (Pubitemid 46211499)
30. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Journal of Oral and Maxillofacial Surgery: Official journal of the American Association of Oral and Maxillofacial Surgeons 2007;65: 415-23. (Pubitemid 46343586)
31. Woo SB, Hellstein JW, Kalmar Jr. Narrative [corrected] review: bispho-sphonates and osteonecrosis of the jaws. Annals of Internal Medicine 2006;144: 753-61.
32. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2009;67: 35-43.
33. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2011.
34. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. American Journal of Clinical Oncology 2012;35: 386-92.
35. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2010;68: 2241-7.
36. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. The Journal of Clinical Endocrinology and Metabolism 2007;92: 1172-5. (Pubitemid 46465699)
37. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2005;63: 1567-75. (Pubitemid 41525412)
38. Zahrowski JJ. Osteonecrosis of the jaws is associated with high-dose bispho-sphonate treatment in patients with cancer. Journal of the American Dental Association (1939) 2010;141: 887-8.
39. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76: 209-11.
40. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, GulleyJL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investigation 2009;27: 221-6.
41. Guarneri V, Miles D, Robert N, Dieras V, GlaspyJ, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment 2010;122: 181-8.
42. Gebara SN, Moubayed H. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. American Journal of Health-system Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists 2009;66: 1541-7.
43. Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 2010;18: 1099-106.
44. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009;20: 117-20.
45. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009;20: 137-45.
46. Fehm T, Felsenberg D, Krimmel M, Solomayer E, Wallwiener D, Hadjii P. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast 2009;18: 213-7.
47. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2007;21: 1545-8. (Pubitemid 46965296)
48. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs. q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. Journal of Clinical Oncology 2012;30: 9005.
49. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia & Lymphoma 2008;49: 2156-62.
50. Lopez-Jornet P, Camacho-Alonso F, Martinez-Canovas A, Molina-Minano F, Gomez-Garcia F, Vicente-Ortega V. Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2011;69: 2488-93.
51. Marx RE, Cillo Jr. JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2007;65: 2397-410. (Pubitemid 350100982)
52. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphos-phonate-associated osteonecrosis of the jaws. Journal of Oral and Maxillofa-cial Surgery: official journal of the American Association of Oral and Maxillofacial Surgeons 2009;67: 1167-73.
53. Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, et al. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2012.
54. Atalay B, Yalcin S, Emes Y, Aktas I, Aybar B, Issever H, et al. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers in Medical Science 2011;26: 815-23.
55. Naik NH, Russo TA. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2009;49: 1729-32.
56. Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. The Laryngoscope 2009;119: 323-9.
57. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2009;67: 850-5.
58. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clinic Proceedings Mayo Clinic 2006;81: 1100-3. (Pubitemid 44175022)
59. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2009;67: 85-95.
60. Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2011;111: 153-63.
61. Voss PJ, Joshi Oshero J, Kovalova-Muller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, et al. Surgical treatment of bisphosphonate-associated osteonecro-sis of the jaw: Technical report and follow up of 21 patients. Journal of Cranio-maxillo-facial Surgery: Official Publication of the European Association for Cranio-Maxillo-Facial Surgery 2012.
62. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, et al. Surgical approach with Er: YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in Medical Science 2010;25: 101-13.
63. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 2009;67: 96-106.
64. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2010;110: 593-6.
65. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. The Journal of Craniofacial Surgery 2007;18: 1071-5. (Pubitemid 47524914)
66. Ripamonti CI, Maniezzo M, Pessi MA, Boldini S. Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report. Tumori 2012;98: 72e-75ee.
67. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral oncology 2011;47: 185-90.
68. Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, et al. Teriparatide and osseous regeneration in the oral cavity. The New England Journal of Medicine 2010;363: 2396-405.
69. Subramanian G, Cohen HV, Quek SY. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2011;112: 744-53.
70. Narvaez J. Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw: reply to Subramanian and Quek. Osteoporosis International: A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012.
71. Miller CS. Teriparatide's potential role in jaw bone related diseases. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2011;112: 703-5.
72. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. The Journal of Oral Implantology 2007;33: 371-82.
73. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011;29: 1221-7.
74. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN task force report: bone health in cancer care. Journal of the National Comprehensive Cancer Network 2009;7 (Suppl. 3): S1-32; quiz S3-5.
75. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002;20: 3719-3736. (Pubitemid 34983232)
76. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008;26: 5904-9.
77. Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein ger-anylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002;30: 64-70. (Pubitemid 34044302)
78. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncology 2009;45: 551-4.